exogenous proteins into living organisms, which is subject to potential risks or technical barriers due to possible aberrant effector activity, delivery limits and immunogenicity.
could alter the protein function without generating any permanent changes to the genome. The ADAR adenosine deaminases are currently exploited to achieve precise base editing on RNAs.
Three kinds of ADAR proteins have been identified in mammals, ADAR1 (isoforms p110 and p150), ADAR2 and ADAR3 (catalytic inactive) 11, 12 , whose substrates are double-stranded RNAs, in which an adenosine (A) mismatched with a cytosine (C) is preferentially deaminated to inosine (I). Inosine is believed to mimic guanosine (G) during translation 13, 14 . To achieve targeted RNA editing, the ADAR protein or its catalytic domain was fused with a λN peptide [15] [16] [17] , a SNAP-tag [18] [19] [20] [21] [22] or a Cas protein (dCas13b) 23 , and a guide RNA was designed to recruit the chimeric ADAR protein to the specific site. Alternatively, overexpressing ADAR1 or ADAR2
proteins together with an R/G motif-bearing guide RNA was also reported to enable targeted RNA editing [24] [25] [26] [27] .
All these reported nucleic acid editing methods in mammalian system rely on ectopic expression of two components: an enzyme and a guide RNA. Although these binary systems work efficiently in most studies, some inherited obstacles limit their broad applications, especially in therapies. Because the most effective in vivo delivery for gene therapy is through viral vectors 28 , and the highly desirable adeno-associated virus (AAV) vectors are limited with cargo size (∼4.5 kb), making it challenging for accommodating both the protein and the guide RNA 29, 30 . Over-expression of ADAR1 has recently been reported to confer oncogenicity in multiple myelomas due to aberrant hyper-editing on RNAs 31 , and to generate substantial global off-targeting edits 32 . In addition, ectopic expression of proteins or their domains of non-human origin has potential risk of eliciting immunogenicity 30, 33 . Moreover, pre-existing adaptive immunity and p53-mediated DNA damage response may compromise the efficacy of the therapeutic protein, such as Cas9 [34] [35] [36] [37] [38] . Although it has been attempted to utilize endogenous mechanism for RNA editing, this was tried only by injecting pre-assembled target transcript:RNA duplex into Xenopus embryos 39 . Alternative technologies for robust nucleic acid editing that don't rely on ectopic expression of proteins are much needed. Here, we developed a novel approach that leverages endogenous ADAR for RNA editing. We showed that expressing a deliberately designed guide RNA enables efficient and precise editing on endogenous RNAs, and corrects pathogenic mutations. This unary nucleic acid editing platform may open new avenues for therapeutics and research.
Leveraging endogenous ADAR for RNA editing
In an attempt to explore an efficient RNA editing platform, we fused the deaminase domain of the hyperactive E1008Q mutant ADAR1 (ADAR1DD) 40 to the catalytic inactive LbuCas13 (dCas13a), an RNA-guided RNA-targeting CRISPR effector 41 (Extended Data Fig. 1a ). To assess RNA editing efficiency, we constructed a surrogate reporter harbouring mCherry and EGFP genes linked by a sequence comprising a 3× GGGGS-coding region and an in-frame UAG stop codon (Reporter-1, Extended Data Fig. 1b) . The reporter-transfected cells only expressed mCherry protein, while targeted editing on the UAG of the reporter transcript could convert the stop codon to UIG and consequently permit the downstream EGFP expression. Such a reporter allows us to measure the A-to-I editing efficiency through monitoring EGFP level. We then designed hU6 promoter-driven crRNAs (CRISPR RNAs) containing 5' scaffolds subjected for Cas13a recognition and variable lengths of spacer sequences for targeting (crRNA Cas13a ,
Supplementary Table 1 ). The sequences complementary to the target transcripts all contain CCA opposite to the UAG codon so as to introduce a cytidine (C) mis-pairing with the adenosine (A) (Extended Data Fig. 1b ) because adenosine deamination preferentially occurs in the A-C mismatch site 13, 14 . To test the optimal length of the crRNA, non-targeting or targeting crRNAs of different lengths were co-expressed with dCas13a-ADAR1DD proteins in HEK293T cells stably expressing the Reporter-1. Evident RNA editing effects indicated by the appearance of EGFP expression were observed with crRNAs containing matching sequences at least 40-nt long, and the longer the crRNAs the higher the EGFP positive percentage (Extended Data Fig. 1c) .
Surprisingly, expression of long crRNA Cas13a alone appeared sufficient to activate EGFP expression, and the co-expression of dCas13a-ADAR1DD rather decreased crRNA activity (Extended Data Fig. 1c, d ). The EGFP expression was clearly sequence-dependent because the 70-nt (exclusive of the 5' scaffold for the length calculation) control RNA could not activate EGFP expression (Extended Data Fig. 1c, d ).
With the surprising finding that certain long engineered crRNA Cas13a enabled RNA editing independent of dCas13a-ADAR1DD, we decided to remove the Cas13a-recruiting scaffold sequence from the crRNA. Because the crRNA70 had the highest activity to trigger EGFP expression (Extended Data Fig. 1c, d ), we chose the same 70-nt long guide RNA without the Cas13a-recruiting scaffold for further test (Fig. 1a and Supplementary Table 2 ). It turned out that this linear guide RNA induced strong EGFP expression in close to 40% of total cells harboring Results the Reporter-1 (Fig. 1b, upper) . Because endogenous ADAR proteins could edit double-stranded RNA (dsRNA) substrates 12 , we reasoned that the long guide RNAs could anneal with the target transcripts to form dsRNA substrates that in turn recruit endogenous ADAR proteins for targeted editing. We thus designated such guide RNA as arRNA (ADAR-recruiting RNA).
To verify if endogenous ADAR proteins are indeed responsible for above observation, we set out to examine the arRNA-mediated RNA editing in ADAR-deficient cells. Since ADAR2 mRNA was barely detectable in HEK293T cells (Extended Data Fig. 2a) , we generated HEK293T ADAR1 -/-cells, rendering this cell line deficient in both ADAR1 and ADAR2 (Fig.   1c, d) . Indeed, the depletion of ADAR1 abrogated arRNA70-induced EGFP signals (Fig. 1b, lower). Moreover, exogenous expression of ADAR1 p110 , ADAR1 p150 or ADAR2 in HEK293T
ADAR1
-/-cells (Fig. 1c, d ) successfully rescued the loss of EGFP induction by arRNA70 (Fig. 1e , Extended Data Fig. 2b ), demonstrating that arRNA-induced EGFP reporter expression solely depended on native ADAR1, whose activity could be reconstituted by its either isoforms (p110 and p150) or ADAR2. Sanger sequencing analysis on the arRNA70-targeting region showed an A/G overlapping peak at the predicted adenosine site within UAG, indicating a significant A to I (G) conversion (Fig. 1f) . The next-generation sequencing (NGS) further confirmed that the A to I conversion rate was about 13% of total reporter transcripts (Fig. 1g) . The quantitative PCR analysis showed that arRNA70 did not reduce the expression of targeted transcripts (Extended Data Fig. 3) , ruling out the possible RNAi effect of the arRNA. Collectively, our data demonstrated that the arRNA is capable of generating significant level of editing on the targeted transcripts through the engineered A-C mismatch. We thus designate this novel RNA editing method as LEAPER (Leveraging Endogenous ADAR for Programmable Editing on RNA).
LEAPER enables RNA editing in multiple cell lines
Because the expression of endogenous ADAR proteins is a prerequisite for LEAPER-mediated RNA editing, we tested the performance of LEAPER in a panel of cell lines originated from distinct tissues, including HT29, A549, HepG2, RD, SF268, SW13 and HeLa. We first examined the endogenous expression of all three kinds of ADAR proteins using Western blotting analyses.
ADAR1 was highly expressed in all tested cell lines, and its identity in the Western blots was confirmed by the negative control, HEK293T ADAR1 -/-line (Fig. 2a, b) . ADAR3 was detected only in HepG2 and HeLa cells (Fig. 2a, b) . ADAR2 was non-detectable in any cells, a result that was not due to the failure of Western blotting because ADAR2 protein could be detected from ADAR2-overexpressing HEK293T cells (Fig. 2a, b) . These findings are in consistent with previous reports that ADAR1 is ubiquitously expressed, while the expressions of ADAR2 and ADAR3 are restricted to certain tissues 11 .
We then set out to test the editing efficiencies of a re-designed 71-nt arRNA (arRNA71)
targeting the Reporter-1 (Extended Data Fig. 4a and Supplementary Table 2) in these cell lines.
LEAPER worked in all tested cells for this arRNA71, albeit with varying efficiencies (Fig. 2c) .
These results were in agreement with the prior report that the ADAR1/2 protein levels correlate with the RNA editing yield 42 , with the exception of HepG2 and HeLa cells. The suboptimal correlations of editing efficiencies with ADAR1 levels were likely due to the abundant ADAR3 expressions in these two lines (Fig. 2a, b ) because it has been reported that ADAR3 plays an inhibitory role in RNA editing 43 . Importantly, LEAPER also worked in three different cell lines of mouse origin (NIH3T3, Mouse Embryonic Fibroblast (MEF) and B16) (Fig. 2d) , paving the way for testing its therapeutics potential through animal and disease models. Collectively, we conclude that LEAPER is a versatile tool for wide-spectrum of cell types, and for different organisms.
Characterization and optimization of LEAPER
To better characterize and optimize LEAPER, we investigated the choices of nucleotide opposite to the adenosine within the UAG triplet of the targeted transcript. In HEK293T cells, Reporter-1-targeting arRNA71 showed variable editing efficiencies with a changed triplet (5'-CNA, N denotes one of A/U/C/G) opposite to the targeted UAG (Supplementary Table 2) . A-C mismatch resulted in the highest editing efficiency, and the A-G mismatch yielded the least but evident edits (Fig. 3a) . We then investigated the preference of nucleotides flanking the A-C mismatch in arRNA. We tested all 16 combinations of 5' and 3' neighbor sites surrounding the cytidine (5'- Table 2) , and found that the 3' neighboring adenosine was required for the efficient editing, while adenosine is the least favorable nucleotide at the 5' site (Fig. 3b, c) .
We thus concluded that CCA motif on the arRNA confers the highest editing efficiency targeting the UAG site. It is worthwhile to note that the 3' neighboring guanosine (5'-N 1 CG) in arRNA showed a dramatic inhibitory effect (Fig. 3b, c) .
Length of RNA appeared relevant to arRNA efficiency in directing the editing on the targeted transcripts (Extended Data Fig. 1c ), consistent with a previous report 42 . To fully understand this effect, we tested arRNAs with variable lengths targeting two different reporter transcriptsReporter-1 and Reporter-2 (Extended Data Fig. 4a, b) . For either reporter targeting, arRNAs of 10 different sizes were designed and tested, ranging from 31-nt to 211-nt, with CCA triplet (for UAG targeting) right in the middle (Supplementary Table 2 ). Based on the reporter EGFP activities, the length of arRNA correlated positively with the editing efficiency, for both reporters, peaking at 111-to191-nt (Fig. 3d) . Although one arRNA51 appeared working, 71-nt was the minimal length for arRNA to work for both reporters (Fig. 3d) .
Next, we investigated the effect of the A-C mismatch position within an arRNA on editing efficiency. We fixed the lengths of all arRNAs for testing to 71-nt, and slided the UAG-targeting ACC triplet from 5' to 3' within arRNAs (Supplementary Table 2 ). It turned out that placing the A-C mismatch in the middle region resulted in high editing yield, and arRNAs with the mismatch sites close to the 3' end outperformed those close to the 5' end in both reporters (Fig.   3e ). For convenience, we placed the A-C mismatch at the center of arRNAs for all of our subsequent studies.
We also tested the targeting flexibility of LEAPER and tried to determine whether UAG on target is the only motif subjected to RNA editing. For all 16 triplet combinations (5'-N 1 AN 2 ) on Reporter-3 (Extended Data Fig. 4c ), we used the corresponding arRNAs with the fixed lengths (111-nt) and ensured the perfect sequencing match for arRNA and the reporter except for the editing site (A-C mismatch) ( Fig. 3f and Supplementary (Fig. 3f, g ). Collectively, the nearest neighbor preference of the target adenosine is 5' U>C≈A>G and 3' G>C>A≈U (Fig. 3g ).
Editing endogenous transcripts using LEAPER
Next, we examined if LEAPER could enable effective editing on endogenous transcripts. Using arRNAs of different lengths, we targeted the UAG motifs in the transcripts of PPIB, KRAS and SMAD4 genes, and an UAC motif in FANCC gene transcript (Fig. 4a, Supplementary Table 2 ).
Encouragingly, targeted adenosine sites in all four transcripts were edited by their corresponding arRNAs with all four sizes, albeit with variable efficiencies according to NGS results (Fig. 4b ).
In consistent with our prior observation, longer arRNAs tended to yield higher editing rates. Of note, the 151-nt arRNA PPIB edited ~50% of total transcripts of PPIB gene (Fig. 4b) Table 2 ), with the efficiency even higher than those with individual arRNAs (Fig. 4d) , indicating that LEAPER is well suited for editing multiple targets in parallel.
It is noteworthy that ADAR1/2 tend to promiscuously deaminate multiple adenosines in an RNA duplex 44 and the A-C mismatch is not the only motif to guide the A-to-I switch (Fig. 3a) . It is therefore reasonable to assume that all adenosines on target transcripts within the arRNA coverages are subjected to variable levels of editing, major sources of unwanted modifications.
The longer the arRNA, the higher the possibility of such off-targets. We therefore examined all adenosine sites within the arRNA covering regions in these targeted transcripts. For PPIB transcripts, very little off-target editing was observed throughout the sequencing window for variable sizes of arRNAs (Fig. 4e, f) . However, in the cases of targeting KRAS, SMAD4 and FANCC genes, multiple off-target edits were detected (Extended Data Fig. 6a-f ). For KRAS in particular, 11 out of 30 adenosines underwent substantial A to I conversions in the sequencing window of arRNA111 (Extended Data Fig. 6a, b) .
We next attempted to develop strategies to minimize such unwanted off-target effects.
Because an A-G mismatch suppressed editing for UAG targeting (Fig. 3a) , we postulated that pairing a guanosine with a non-targeting adenosine might reduce undesirable editing. We then Table 2) . A-G mismatch indeed decreased the editing on adenosine in all tested targets, except for UAG or AAG targeting (～2%) (Fig. 4g ), in comparison with A-C mismatch (Fig. 3f) . To further reduce editing rates at unwanted sites, we went on testing the effect of two consecutive mismatches. It turned out that the additional mismatch at the 3' end nucleotide of the triplet opposite to either UAG or AAG, abolished its corresponding adenosine editing ( Fig. 4h and Supplementary Table 2 ). In light of these findings, we attempted to apply this rule to reduce off-targets in KRAS transcripts (Extended Data Fig. 6a ). We first designed an arRNA (arRNA111-AG6) that created A-G mismatches on all "editing-prone" motifs covered by arRNA111 ( Table 2 ). Consequently, we achieved a much improved specificity for editing, without additional loss of editing rate on the targeted site (A76) (Fig. 4i ).
In summary, engineered LEAPER incorporating additional rules enables efficient and more precise RNA editing on endogenous transcripts.
RNA editing specificity of LEAPER
In addition to the possible off-target effects within the arRNA-covered dsRNA region, we were also concerned about the potential off-target effects on other transcripts through partial base pairing of arRNA. We then performed a transcriptome-wide RNA-sequencing analysis to evaluate the global off-target effects of LEAPER. Cells were transfected with a Ctrl RNA151 or a PPIB-specific arRNA (arRNA151-PPIB) expressing plasmids before subjected to RNA-seq analysis. We identified six potential off-targets in the Ctrl RNA151 group (Fig. 5a ) and five in the arRNA151-PPIB group (Fig. 5b) , and the PPIB on-target rate based on NGS analysis was ~37%
( Fig. 5b ). Further analysis revealed that all sites, except for the two sites from EIF2AK2 transcripts, were located in either SINE (Alu) or LINE regions (Fig. 5a , b), both are prone to ADAR-mediated editing 45 , suggesting that these off-targets may not be derived from pairing between the target transcripts and the arRNA or control RNA. Of note, two off-targeting transcripts, WDR73 and SMYD4, appeared in both groups, suggesting they are unlikely sequence-dependent RNA editing. Indeed, minimum free energy analysis suggested that all these possible off-target transcripts failed to form a stable duplex with either Ctrl RNA151 or arRNA151-PPIB ( Fig. 5c ). To further test if arRNA generates sequence-dependent off-targets, we selected potential off-target sites by comparing sequence similarity using NCBI BLAST for both arRNA151-PPIB and arRNA111-FANCC. TRAPPC12 transcripts for arRNA151-PPIB and three sites in the ST3GAL1, OSTM1-AS1 and EHD2 transcripts for arRNA111-FANCC were top candidates ( Fig. 5d and Extended Data Fig. 7a ). NGS analysis revealed that no editing could be detected in any of these predicted off-target sites ( Fig. 5d and Extended Data Fig. 7b ). These results indicate that LEAPER empowers efficient editing at the targeted site, while maintaining transcriptome-wide specificity without detectable sequence-dependent off-target edits.
Safety assessment of LEAPER in mammalian cells
Because arRNAs rely on endogenous ADAR proteins for editing on target transcripts, we wondered if the addition of exogenous arRNAs affects native RNA editing events by occupying too much of ADAR1 or ADAR2 proteins. Therefore, we analyzed the A-to-I RNA editing sites shared by mock group and arRNA151-PPIB group from the transcriptome-wide RNA-sequencing results, and the comparison between the mock group and Ctrl RNA151 group was also analyzed.
Neither Ctrl RNA151 group nor arRNA151-PPIB group showed a significant difference compared to the mock group (Fig. 6a, b ), indicating that LEAPER had little impact on the normal function of endogenous ADAR1 to catalyze the native A-to-I editing events.
Meanwhile, we performed differential gene expression analysis using RNA-seq data to verify whether arRNA affects global gene expression. We found that neither Ctrl RNA151 nor arRNA151-PPIB affected the global gene expression in comparison with the mock group ( Fig. 6c,   d ). In consistent with our prior observation (Extended Data Fig. 5a ), arRNAs did not show any
RNAi effect on the expression of PPIB (Fig. 6c, d ).
Considering that the arRNA forms RNA duplex with the target transcript and that RNA duplex might elicit innate immune response, we investigated if the introduction of arRNA has such an effect. To test this, we selected arRNAs targeting four gene transcripts that had been proven effective. We did not observe any mRNA induction of interferon-β (IFN-β) ( 
Recovery of transcriptional regulatory activity of p53 by LEAPER
Now that we have established a novel method for RNA editing without the necessity of introducing foreign proteins, we attempted to demonstrate its therapeutic utility. We first targeted the tumor suppressor gene TP53, which is known to play a vital role in the maintenance of cellular homeostasis, but undergo frequent mutations in >50% of human cancers 46 . The c.158G>A mutation in TP53 is a clinically-relevant nonsense mutation (Trp53Ter), resulting in a non-functional truncated protein 46 . We designed one arRNA111 and two alternative arRNAs (arRNA111-AG1 and arRNA111-AG4) (Supplementary and arRNA111-AG4 (Extended Data Fig. 8 ). Western blot showed that arRNA111, arRNA111-AG1
and arRNA111-AG4 could all rescue the production of full-length p53 protein based on the TP53 W53X transcripts in HEK293T TP53 -/-cells, while the Ctrl RNA111 could not (Fig. 7c ).
To verify whether the repaired p53 proteins are fully functional, we tested the transcriptional regulatory activity of p53 with a p53-luciferase cis-reporting system 47, 48 . All three versions of arRNAs could restore p53 activity, and the optimized version arRNA111-AG1 performed the best (Fig. 7d) . In conclusion, we demonstrated that LEAPER is capable of repairing the cancerrelevant pre-mature stop codon of TP53 and restoring its function.
Corrections of pathogenic mutations by LEAPER
We next investigated whether LEAPER could be used to correct more pathogenic mutations.
Aiming at clinically relevant mutations from six pathogenic genes, COL3A1 of Ehlers-Danlos syndrome, BMPR2 of Primary pulmonary hypertension, AHI1 of Joubert syndrome, FANCC of Fanconi anemia, MYBPC3 of Primary familial hypertrophic cardiomyopathy and IL2RG of Xlinked severe combined immunodeficiency, we designed 111-nt arRNAs for each of these genes carrying corresponding pathogenic G>A mutations (Extended Data Fig. 9 and Supplementary Tables 2, 3 ). By co-expressing arRNA/cDNA pairs in HEK293T cells, we identified significant amounts of target transcripts with A>G corrections in all tests (Fig. 8) . Because G>A mutations account for nearly half of known disease-causing point mutations in humans 10, 49 , the A>G conversion by LEAPER may offer immense opportunities for therapeutics.
RNA editing in multiple human primary cells by LEAPER
To further explore the clinical utility of LEAPER, we set out to test the method in multiple human primary cells. First, we tested LEAPER in human primary pulmonary fibroblasts and human primary bronchial epithelial cells with 151-nt arRNA (Supplementary Table 2 ) to edit the Reporter-1 (Extended Data Fig. 4a ). 35-45% of EGFP positive cells could be obtained by LEAPER in both human primary cells (Fig. 9a) . We then tested LEAPER in editing endogenous gene PPIB in these two primary cells and human primary T cells, and found that arRNA151-PPIB could achieve >40%, >80% and >30% of editing rates in human primary pulmonary fibroblasts, primary bronchial epithelial cells (Fig. 9b ) and primary T cells (Fig. 9c) , respectively. The high editing efficiency of LEAPER in human primary cells is particularly encouraging for its potential application in therapeutics.
Efficient editing by lentiviral expression and chemical synthesis of arRNAs
We then investigated if LEAPER could be delivered by more clinically-relevant methods. We first tested the effect of arRNA through lentivirus-based expression. Reporter-1-targeting arRNA151 induced strong EGFP expression in more than 40% of total cells harboring the Reporter-1 in HEK293T cells 2 days post infection (dpi). At 8 dpi, the EGFP ratio maintained at a comparable level of ~38% ( Fig. 10a and Supplementary Table 2 ), suggesting that LEAPER could be tailored to therapeutics that require continuous administration. For native gene editing, we delivered PPIB-targeting arRNA151 through lentiviral transduction in HEK293T cells and observed over 6% of target editing at 6 dpi (Fig. 10b) .
We next tested synthesized arRNA oligonucleotides and electroporation delivery method for LEAPER. The 111-nt arRNA targeting PPIB transcripts as well as Ctrl RNA were chemically synthesized with 2'-O-methyl and phosphorothioate linkage modifications at the first three and last three residues of arRNAs (Fig. 10c) . After introduced into T cells through electroporation, arRNA111-PPIB oligos achieved ~20% of editing on PPIB transcripts (Fig. 10d) , indicating that LEAPER holds promise for the development of oligonucleotide drugs. IDUA-V2 performed much better than arRNA111-IDUA-V1, while no α-L-iduronidase activity could be detected in three control groups (Fig. 11b) .
Restoration of α-L-iduronidase activity in
To further evaluate the extent to which the restored IDUA activity in GM06214 by LEAPER relieves the Hurler syndrome, we examined the IDUA activity in GM01323 cells, another primary fibroblasts from patient with Scheie syndrome, a much milder subtype of MPS I than
Hurler syndrome due to the remnant IDUA activity resulting from heterozygous genotype on IDUA gene. We found that the catalytic activity of IDUA in GM06214 cells harbouring arRNA111-IDUA-V2 was higher than GM01323 cells 48 hr post electroporation (Fig. 11b) .
Consistent with these results, NGS analysis indicated that arRNA111-IDUA-V2 converted nearly 30% of A to I editing, a much higher rate than arRNA111-IDUA-V1 (Fig. 11c) . Further analysis revealed that minimal unwanted edits were detected within the arRNA covered regions of IDUA transcripts (Fig. 11d) . Importantly, LEAPER did not trigger immune responses in primary cells as we demonstrated that, unlike the RNA duplex poly(I:C) serving as a positive control, neither arRNA111-IDUA-V1 nor arRNA111-IDUA-V2 induced expressions of a panel of genes involved in type-I interferon and pro-inflammatory responses (Fig. 11e) . These results showed the therapeutic potential of LEAPER in targeting certain monogenetic diseases.
Discussion
In this report, we showed that expression of a linear arRNA with adequate length is capable of guiding endogenous ADAR proteins to edit adenosine to inosine on the targeted transcripts. This system, referred to as LEAPER, utilizes endogenous ADAR proteins to achieve programmable nucleic acid editing, thus possessing advantages over existing approaches.
The rare quality of LEAPER is its simplicity because it only relies on a small size of RNA molecule to direct the endogenous proteins for RNA editing. This is reminiscent of RNAi, in which a small dsRNA could invoke native mechanism for targeted RNA degradation 51 . Because of the small size, arRNA could be readily delivered by a variety of viral and non-viral vehicles.
Different from RNAi, LEAPER catalyzes the precise A to I switch without generating cutting or degradation of targeted transcripts (Extended Data Fig. 5a ). Although the length requirement for arRNA is longer than RNAi, it neither induces immune-stimulatory effects at the cellular level (Fig. 6e, f and Fig. 11e ) nor affects the function of endogenous ADAR proteins (Fig. 6a, b) , making it a safe strategy for RNA targeting. Remarkably, it has been reported that ectopic expression of ADAR proteins or their catalytic domains induces substantial global off-target edits 32 and possibly triggers cancer 31 .
Recently, several groups reported that cytosine base editor could generate substantial off-target single-nucleotide variants in mouse embryos, rice or human cell lines due to the expression of an effector protein, which illustrates the advantage of LEAPER for potential therapeutic application [52] [53] [54] . Gratifyingly, LEAPER empowers efficient editing while elicits rare global offtarget editing ( Fig. 5 and Extended Data Fig. 7 ). In addition, LEAPER could minimize potential immunogenicity or surmount delivery obstacles commonly shared by other methods that require the introduction of foreign proteins.
For LEAPER, we would recommend using arRNA with a minimal size above 70-nt to achieve desirable activity. In the native context, ADAR proteins non-specifically edit Alu repeats which have a duplex of more than 300-nt 55 . Of note, Alu repeats form stable intramolecular duplex, while the LEAPER results in an intermolecular duplex between arRNA and mRNA or premRNA, which is supposed to be less stable and more difficult to form. Therefore, we hypothesized that an RNA duplex longer than 70-nt is stoichiometrically important for recruiting or docking ADAR proteins for effective editing. Indeed, longer arRNA resulted in higher editing yield in both ectopically expressed reporters and endogenous transcripts ( Fig. 3d and Fig. 4b ).
However, because ADAR proteins promiscuously deaminate adenosine base in the RNA duplex, longer arRNA may incur more off-targets within the targeting window.
While LEAPER could effectively target native transcripts, their editing efficiencies and offtarget rates varied. For PPIB transcript-targeting, we could convert 50% of targeted adenosine to inosine without evident off-targets within the covering windows (Fig. 4b, f) . The off-targets became more severe for other transcripts. We have managed to reduce off-targets such as introducing A-G mismatches or consecutive mismatches to repress undesired editing. However, too many mismatches could decrease on-target efficiency. Weighing up the efficiency and potential off-targets, we would recommend arRNA with the length ranging from 100-to 150-nt for editing on endogenous transcripts. If there is a choice, it's better to select regions with less adenosine to minimize the chance of unwanted edits. Encouragingly, we have not detected any off-targets outside of the arRNA-targeted-transcript duplexes (Fig. 5) .
We have optimized the design of the arRNA to achieve improved editing efficiency and demonstrated that LEAPER could be harnessed to manipulate gene function or correct pathogenic mutation. We have also shown that LEAPER is not limited to only work on UAG, instead that it works with possibly any adenosine regardless of its flanking nucleotides (Fig. 3f, g and Fig. 4c ). Such flexibility is advantageous for potential therapeutic correction of genetic diseases caused by certain single point mutations. Interestingly, in editing the IDUA transcripts, the arRNA targeting pre-mRNA is more effective than that targeting mature RNA, indicating that nuclei are the main sites of action for ADAR proteins and LEAPER could be leveraged to manipulate splicing by modifying splice sites within pre-mRNAs. What's more, LEAPER has demonstrated high efficiency for simultaneously targeting multiple gene transcripts (Fig. 4d ).
This multiplexing capability of LEAPER might be developed to cure certain polygenetic diseases in the future.
It is beneficial to perform genetic correction at the RNA level. First, editing on targeted transcripts would not permanently change the genome or transcriptome repertoire, making RNA editing approaches safer for therapeutics than means of genome editing. In addition, transient editing is well suited for temporal control of treating diseases caused by occasional changes in a specific state. Second, LEAPER and other RNA editing methods would not introduce DSB on the genome, avoiding the risk of generating undesirable deletions of large DNA fragments 37 .
DNA base editing methods adopting nickase Cas9 could still generate indels in the genome 8 .
Furthermore, independent of native DNA repair machinery, LEAPER should also work in postmitosis cells such as cerebellum cells with high expression of ADAR2 11 .
We have demonstrated that LEAPER could apply to a broad spectrum of cell types such as human cell lines (Fig. 2c) , mouse cell lines (Fig. 2d) and human primary cells including primary T cells (Fig. 9 and Fig. 10d ). Efficient editing through lentiviral delivery or synthesized oligo provides increased potential for therapeutic development (Fig. 10) . Moreover, LEAPER could produce phenotypic or physiological changes in varieties of applications including recovering the transcriptional regulatory activity of p53 (Fig. 7) , correcting pathogenic mutations (Fig. 8) , and restoring the α-L-iduronidase activity in Hurler syndrome patient-derived primary fibroblasts (Fig. 11) . It can thus be envisaged that LEAPER has enormous potential in disease treatment.
While our manuscript was under revision, Stafforst and colleagues reported a new and seemingly similar RNA editing method, named RESTORE, which works through recruiting endogenous ADARs using synthetic antisense oligonucleotides 56 . The fundamental difference between RESTORE and LEAPER lies in the distinct nature of the guide RNA for recruiting endogenous ADAR. The guide RNA of RESTORE is limited to chemosynthetic antisense oligonucleotides (ASO) depending on complex chemical modification, while arRNA of LEAPER can be generated in a variety of ways, chemical synthesis and expression from viral or non-viral vectors ( Fig. 10 and Fig. 11 ). Importantly, being heavily chemically modified, ASOs is restricted to act transiently in disease treatment. In contrast, arRNA could be produced through expression, a feature particularly important for the purpose of constant editing.
There are still rooms for improvements regarding LEAPER's efficiency and specificity.
Because LEAPER relies on the endogenous ADAR, the expression level of ADAR proteins in target cells is one of the determinants for successful editing. According to previous report 57 and our observations (Fig. 2a, b) , the ADAR1 p110 is ubiquitously expressed across tissues, assuring the broad applicability of LEAPER. The ADAR1 p150 is an interferon-inducible isoform 58 , and has proven to be functional in LEAPER (Fig. 1e, Extended Data Fig. 2b) Altogether, we provided a proof of principle that the endogenous machinery in cells could be co-opted to edit RNA transcripts. We demonstrated that LEAPER is a simple, efficient and safe system, shedding light on a novel path for gene editing-based therapeutics and research. all indicate the mean ± s.e.m. (n = 3); unpaired two-sided Student's t-test, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant. The indicated arRNAs or the poly(I:C) were transfected into HEK293T cells. Total RNA was then analyzed using quantitative PCR to determine expression levels of IFN-β (e) and IL-6 (f).
Data (e and f) are presented as the mean ± s.e.m. (n = 3). Student's t-test, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant. 
Methods

Plasmids construction
For the three versions of dual fluorescence reporters (Reporter-1, -2 and -3), mCherry and EGFP (the start codon ATG of EGFP was deleted) coding sequences were PCR amplified, digested using BsmBI (Thermo Fisher Scientific, ER0452), followed by T4 DNA ligase (NEB, M0202L)-mediated ligation with GGGGS linkers. The ligation product was subsequently inserted into the pLenti-CMV-MCS-PURO backbone.
For the dLbuCas13-ADAR DD (E1008Q) expressing construct, the ADAR1DD gene was amplified from the ADAR1 p150 construct (a gift from Jiahuai Han's lab, Xiamen University). The Table 4 ). The PCR products were purified for Sanger sequencing or NGS (Illumina HiSeq X Ten).
RNA editing analysis for targeted sites
For deep sequencing analysis, an index was generated using the targeted site sequence The bioinformatics analysis pipeline was referred to the work by Vogel et al 22 . The quality control of analysis was conducted by using FastQC, and quality trim was based on Cutadapt (the first 6-bp for each reads were trimmed and up to 20-bp were quality trimmed). AWK scripts were used to filtered out the introduced arRNAs. After trimming, reads with lengths less than 90-nt were filtered out. Subsequently, the filtered reads were mapped to the reference genome (GRCh38-hg38) by STAR software 61 . We used the GATK Haplotypcaller 62 to call the variants.
The raw VCF files generated by GATK were filtered and annotated by GATK VariantFiltration, Fig. 6 .
X means the editing rate of each site in the Mock group; Y means the editing rate of each site in the Ctrl RNA151 group (Fig. 6a ) or arRNA151-PPIB group (Fig. 6b) ; σx is the standard deviation of X; σY is the standard deviation of Y; μX is the mean of X; μY is the mean of Y; E is the expectation.
The RNA-Seq data were analysed for the interrogation of possible transcriptional changes induced by RNA editing events. The analysis of transcriptome-wide gene expression was performed using HISAT2 and STRINGTIE software 65 . We used Cutadapt and FastQC for the quality control of the sequencing data. The sequencing reads were then mapped to reference genome (GRCh38-hg38) using HISAT2, followed by Pearson's correlation coefficient analysis as mentioned above.
Western blot
We used the mouse monoclonal primary antibodies respectively against ADAR1 (Santa Cruz, sc- Table 4 .
Transcriptional regulatory activity assay of p53
The TP53 W53X cDNA-expressing plasmids and arRNA-expressing plasmids were co-transfected into HEK293T TP53 -/-cells, together with p53-Firefly-luciferase cis-reporting plasmids (YRGene, VXS0446) and Renilla-luciferase plasmids (a gift from Z. Jiang's laboratory, Peking University) for detecting the transcriptional regulatory activity of p53. 48 hrs later, the cells were harvested and assayed with the Promega Dual-Glo Luciferase Assay System (Promega, E4030) according to the manufacturer protocol. Briefly, 150 μL Dual-Glo Luciferase Reagent was added to the harvested cell pellet, and 30 minutes later, the Firefly luminescence was measured by adding 100 μL Dual-Glo Luciferase Reagent (cell lysis) to 96-well white plate by Infinite M200 reader (TECAN). 30 min later, 100 μL Dual-Glo stop and Glo Reagent were sequentially added to each well to measure the Renilla luminescence and calculate the ratio of Firefly luminescence to Renilla luminescence.
Electroporation in primary cells
For arRNA-expressing plasmids electroporation in the human primary pulmonary fibroblasts or human primary bronchial epithelial cells, 20 μg plasmids were electroporated with 
